力生制药：氯化钾缓释片通过上市许可申请

Core Viewpoint - The company, Lifesun Pharmaceutical, has received drug registration certificates for its potassium chloride sustained-release tablets in two specifications, indicating successful approval for market entry [1] Group 1: Company Developments - Lifesun Pharmaceutical announced the receipt of drug registration certificates from the National Medical Products Administration for potassium chloride sustained-release tablets in 0.5g and 0.6g specifications [1] - The potassium chloride sustained-release tablets are indicated for the treatment and prevention of hypokalemia associated or not associated with metabolic alkalosis, particularly when dietary management or reduced diuretic dosage is ineffective [1]